NDB Advisory Announces Firm Expansion to Contain PCI Compliance Auditing for Alabama Businesses


Birmingham, AL (PRWEB) June 30, 2013

Alabama firms now have a high-quality, trusted supply in supplying price-effective options for compliance with the Payment Card Market Data Security Requirements (PCI DSS) provisions – NDB Advisory. From providing PCI Readiness Assessments to Level 1 onsite Report on Compliance (RoC) assessments by a PCI-QSA, NDB Advisory is your go to firm for Alabama PCI services. Call and speak directly with PCI-QSA Charles Denyer at 1-800-277-5415, ext. 705 or email him at cdenyer(at)ndbcpa(dot)com. Charles has been a licensed PCI-QSA for many years, assisting organization all around North America in implementing extensive, yet cost-effective PCI compliance solutions. For Alabama companies involved in the storing, processing, and/or transmitting of cardholder information, PCI compliance is a strict requirement, so talk to the trusted experts nowadays at NDB Advisory. NDB Advisorys Alabama PCI DSS solutions consist of the following:&#13

&#13

New Fibromyalgia (FM) Clinical Trial Now Enrolling at Attain Clinical Analysis in Birmingham, Alabama Accepting M/F Patients with Fibromyalgia Age 18-70


Birmingham, Alabama (PRWEB) June 30, 2013

ESTIMATED STUDY DURATION:&#13

16-19 weeks. This involves 5 28 days in screening followed by 16 weeks of blinded study drug treatment.

&#13

BACKGROUND &amp RATIONALE:&#13

Chronic discomfort affects an estimated 116 million American adults– much more than the total affected by heart disease, cancer and diabetes combined. Chronic pain is estimated to cost the U.S. $ 560-635 billion annually in direct healthcare remedy expenses and lost productivity. Discomfort is a key driver for visits to physicians, a key purpose for taking medication, a significant trigger of disability, and a key issue in high quality of life and productivity. Given the burden of pain on human lives and its many economic and social consequences, relieving pain could be considered a national priority. Fibromyalgia individuals constitute a developing, main cohort of chronic pain sufferers, and finding successful treatments for this disease represents an urgent challenge each to the field of medicine and to the U.S. economy.

&#13

Fibromyalgia syndrome (FM) is a typical disorder estimated to have an effect on two to four% of the population. Although FM is predominantly identified by the presence of chronic widespread discomfort, patients with fibromyalgia typically experience a selection of other program symptoms such as fatigue, non-restorative sleep, morning stiffness and cognitive dysfunction they may also be diagnosed with other comorbid discomfort situations such as migraine, irritable bowel syndrome, temperomandibular joint disorder (TMJ), interstitial cystitis and chronic pelvic pain.

&#13

Major OBJECTIVES:&#13

The primary objective of this study is to evaluate the security and efficacy of a new Fibromyalgia drug as a treatment for patients with main fibromyalgia. The primary efficacy outcome measure will be the patients self-reported 24-hour recall typical discomfort intensity, evaluated on an 11 point numerical rating scale, comparing alter from baseline benefits over 16 weeks of remedy with a new Fibromyalgia drug or placebo.

&#13

The safety and tolerability of therapy with a new Fibromyalgia drug will be compared to placebo by evaluation of important indicators, laboratory parameters, therapy-related adverse events (TEAEs), and discontinuations due to adverse events.

&#13

SECONDARY OBJECTIVES:&#13

1. Comparison of the efficacy of a new Fibromyalgia drug versus placebo primarily based on the outcomes of the self-reported Patient Worldwide Impression of Adjust (PGIC). Efficacy will be defined by the percentage of patients who rate themselves as very a lot enhanced or much enhanced (i.e., scores of 1 or two on the 1-7 point scale) at the end of therapy.

&#13

two. Comparison of the efficacy of a new Fibromyalgia drug versus placebo on the 7-day recall discomfort query of the FIQ-R.

&#13

three. Comparison of the efficacy of a new Fibromyalgia drug versus placebo on the Revised Fibromyalgia Effect Questionnaire (FIQR) total score.

&#13

4. Comparison of the efficacy of a new Fibromyalgia drug versus placebo on the 24 hour recall typical pain intensity NRS score obtained at Weeks six and 12.

&#13

INCLUSION CRITERIA:

&#13

1. Prepared and in a position to study, realize, and sign the informed consent

&#13

two. Male or female, 18 -70 years of age, inclusive

&#13

3. Each and every female patient have to have a unfavorable urine pregnancy test at Screening and Baseline unless post-menopausal (defined as no menses for at least 1 year) or surgically sterile (s/p hysterectomy, bilateral oophorectomy or bilateral tubal ligation)

&#13

4. Females of kid-bearing prospective should be willing to use an efficient birth handle technique for the duration of the study. Women involved in same sex relationships or committed to sexual abstinence (e.g., for religious motives) will be excluded from this requirement.

&#13

Allowable contraceptive methods consist of: &#13

a. Oral, implantable, injectable or transdermal hormonal contraceptives (need to have been utilised for a minimum of 1 full cycle prior to administration of study drug) &#13

b. Intrauterine devices (IUD) &#13

c. Vasectomized companion &#13

d. Double barrier approach (male or female condom, sponge, diaphragm or vaginal ring with simultaneous use of spermicidal agent)

&#13

5. Diagnosis of principal fibromyalgia (FM) as defined by the 2010 American College of Rheumatology Preliminary Diagnostic Criteria for Fibromyalgia

&#13

six. Patients need to be prepared and capable to withdraw from the following therapies: duloxetine, milnacipran, pregabalin, gabapentin, sodium oxybate, narcotics and opioids.

&#13

7. Sufferers need to have a damaging drug screen for narcotics and opioids prior to completion of the Baseline go to.

&#13

eight. Sufferers have to be willing and capable to withdraw and refrain from the use of other NSAIDs.

&#13

9. Certified individuals with mild or moderate depression ought to be clinically stable, with no threat of suicidal ideation or behavior, and the dose of allowed anti-depressants ought to have been stable for at least three months prior to screening.

&#13

ten. Individuals ought to not call for therapy with warfarin, lithium, amiodarone, isoniazid, phenytoin, fluconazole, probenecid or raloxifene.

&#13

11. At the Screening pay a visit to, patient must have a 24 hour recall average discomfort intensity score among 40 and 90 inclusive on a 100 mm VAS scale.

&#13

12. At the Baseline go to, the patient should have a 24 hour recall typical pain intensity score among four and 9 inclusive on an 11 point numerical rating scale.

&#13

13. In the opinion of the Investigator, the patient is prepared and in a position to comply with all protocol-specified needs

&#13

*To see if you qualify for this Fibromyalgia Clinical Trial in Alabama, pay a visit to Obtain Clinical Analysis on the internet (http://www.achieveclinical.com) or speak to us straight at (205) 380-6434.

&#13

*Accomplish Clinical Research conducts Phase II-IV Clinical Trials in Alabama. For a lot more information about participating in a Fibromyalgia Clinical Study, please visit our web site or speak to us straight at (205) 380-6434.

&#13
&#13
&#13
&#13
&#13

Uncover Much more Administrator Press Releases

Alabama Lawyer General and BP Settlement Administrator to Meet with North Alabama Organization Men and Ladies to Explain BP Settlement


Birmingham, Alabama (PRWEB) June 04, 2013

Alabama Attorney Common Luther Strange and BP Settlement Administrator Patrick Juneau have scheduled 3 meetings to talk about how the BP Settlement applies to North Alabama organizations on Wednesday, June 5, 2013.

&#13

Michael J. Evans, an lawyer representing North Alabama companies filing BP Settlement claims, mentioned: “Each and every North Alabama business man and lady who can attend the meetings with the Lawyer Common and BP Settlement Administrator on Wednesday must do so, since his or her organization may possibly be in a position to collect a large amount of income. Numerous North Alabama companies might qualify for massive BP Settlement payments without having knowing it. For these unable to attend the meetings, they can view a video explaining how the BP settlement applies to North Alabama businesses at the BP Settlement Help site.”

&#13

Lawyer Common Strange and BP Settlement Administrator Juneau will aid company owners and individuals understand the eligibility and proof needs for submitting a BP claim.

&#13

Evans said he is concerned that a lot of folks will be unable to attend the meetings, which, Evans stated, “may be also short.” The meetings are set from 9-10 a.m. at the Cullman Area Chamber of Commerce, 301 Second Ave. S.W. 11:30 a.m.-1:30 p.m. at the Chamber of Commerce of Huntsville/Madison County, 225 Church St. and 3:30-four:30 p.m. at Harbert Center, 2019 Fourth Ave. in Birmingham.

&#13

“If a enterprise owner is not capable to attend one particular of the meetings,” Evans said, “that person can get much more details from a BP claims news website, or watch a set of videos explaining the BP settlement.

&#13

Evans has joined forces with the Birmingham law firms of Yearout &amp Traylor, P.C. and Gathings Law to manage BP claims for North Alabama companies. “All of our websites have make contact with forms that let companies to request a free of charge legal review of potential BP claims by an lawyer. Company owners could also call the law firms directly. Attorney Gusty Yearout can be reached at 800-226-6116 and Lloyd Gathings can be known as at 877-803-3006. North Alabama businesses can seek the advice of with attorneys about prospective BP claims on the phone, in an office appointment, or by utilizing a website speak to form.”

&#13

Sources:

&#13

http://www.al.com/company/index.ssf/2013/05/alabama_ag_luther_strange_to_h.html

&#13

http://alabamatruth.com/alabama-ag-luther-strange-to-hold-3-public-briefings-on-deepwater-horizon-oil-spill-subsequent-week/

&#13

The term “BP Settlement” refers to the settlement in In Re: Oil Spill by the Oil Rig Deepwater Horizon in the Gulf of Mexico, on April 20, 2010, MDL NO. 2179, that was ultimately approved by U.S. District Judge Carl Barbier on December 21, 2012, and filed on that date in the United States District Court for the Eastern District of Louisiana. A copy of the Final Order and Judgment are attached to this press release.

&#13

About Michael J. Evans

&#13

Michael J. Evans is an attorney and is the owner of the Law Offices of Michael J. Evans, located in Birmingham, AL 35255. Lawyer Michael J. Evans has a background in mass tort and complicated litigation, each locally in Alabama and nationally making use of the World wide web. Lawyer Evans has in depth experience employing the World wide web and social media to connect injured consumers with law firms nationwide.

&#13

Speak to: &#13

Attorney Michael J. Evans &#13

Law Offices of Michael J. Evans, LLC &#13

P.O. Box 55055 &#13

Birmingham, AL 35255 &#13

205-999-3726 &#13

mjevans(at)mjevans(dot)com

&#13

Marketing disclaimer: No representation is made that the quality of legal services to be performed is greater than the high quality of legal solutions performed by other lawyers. The hiring of a law firm is a critical decision that need to not be based on advertising alone.

&#13
&#13
&#13
&#13
&#13

Far more Administrator Press Releases